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Abstract
Background: Adenoid cystic carcinomas are rare tumors with an indolent clinical course, but
frequent local relapses. The identification of tumors with a higher relapse risk seems to be
interesting. Hence we investigated parameters of glucose metabolism, which were found associated
with poor prognosis in other malignancies.
Methods: Specimen of 29 patients were investigated immunohistochemically with antibodies
against p-AKT, TKTL-1 (transketolase-like 1), M2PK (M2 pyruvate kinase), and GLUT-1.
Proliferation was investigated by staining with Ki67. The tumors were located at the major or
minor salivary glands. Only the typical cribriform subtype was investigated. The initial tumor stage
was pT1 or pT2.
Results: Expression of p-AKT was significantly (P = 0.036) associated with a higher relapse risk in
multivariate analysis. Low expression of M2PK was non-significantly (P = 0.065) predictive for a
higher risk. TKTL-1 and GLUT-1 were expressed in the majority of cases, albeit not associated with
relapse risk.
Conclusion: Adenoid cystic carcinomas positive for p-AKT show a higher relapse risk. However,
other parameters of glucose metabolism investigated here or proliferation (Ki67) were not
predictive in this entity. Our findings demonstrate a possible background for therapeutic
approaches targeting the inhibition of PI3K/AKT pathway.
Background
Malignant tumors of salivary glands represent a small sub-
set of all malignancies. Adenoid cystic carcinomas (ACC)
are one of the most common types at this anatomic site.
They account for 1% of all malignant head and neck
tumors, 10% of all salivary gland tumors, and 22% of
malignant salivary gland tumors [1,2]. The majority
occures at the minor salivary glands (60%) [3]. From the
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Locations like the nasal cavity and the paranasal sinus are
also possible. Typically, ACC show an indolent clinical
course with a considerable risk for local relapse (60% of
patients, mostly <2 years after primary) and late distant
metastases (lung or bone), the latter sometimes several
years after first diagnosis with fatal outcome. Standard
treatment for ACC is surgery, followed by post-operative
radiotherapy [4]. Since tumors show a characteristic
perineural spread, the surgical key problem is the com-
plete resection. Therefore, the extend of tumor infiltration
is sometimes not apparent, and local relapses may origi-
nate from microscopic residual disease.
The therapeutic options have not been improved signifi-
cantly in recent years despite different studies which
investigated the influence of chemotherapy or molecular
approaches [3,5,6]. However, there are individual differ-
ences concerning the outcome. To estimate prognosis,
tumor stage, subtype, and the extend of perineural spread
were found to be reliable.
In order to identify additional predictive parameters by
immunohistochemical investigation, we performed the
following study. The intention herein was to clarify the
predictive potential of the expression of several markers
which are assumed to play an important role in the glu-
cose metabolism, especially phosphorylated AKT (p-
AKT), transketolase-like-1 (TKTL-1), M2 pyruvate kinase
(M2PK), and glucose transporter (GLUT-1). Their expres-
sion was found associated with a poor prognosis in differ-
ent malignancies [7-15]. To our knowledge, these
parameters were not investigated in ACC up to now. The
idea for this study is based on the theory of Otto Heinrich
Warburg (1883–1970) from 1924, which implies the
increase of glucose utilization in all malignant tumors
[16].
Methods
Paraffin embedded tumor specimens of 29 patients (16
female, 13 male) with ACC were included in this study.
The locations of primaries are indicated in table 1. In cases
with relapses, primaries and their relapses were examined.
The time of follow up observation was at least five years.
The initial therapy was surgical with consecutive local
radiation in all cases. Tumors investigated in this study
had a initial tumor stage of pT1 or pT2, N0, M0.
Three histological subtypes of ACC exist (cribriform,
solid, tubular). Due to the known differences in prognosis
[2], only cases with the typical cribrifom pattern of growth
and typical immunophenotyp (Vimentin +, CD117 +)
were included. Diagnoses were validated by two experi-
enced pathologists.
Immunohistochemical staining
Immunohistochemical staining with commercially avail-
able antibodies were done in standard technique follow-
ing manufacturer's protocols. Positive controls were used
in accordance with manufacturer's recommendations or
own established/published experiences. Antibodies
including provider, dilution and positive controls are
listed in table 2. All sections including positive controls
were stained simultaneously for the appropriate antibody.
Slides with tumor sections with a maximum thickness of
2–5 μm were deparaffinized with xylene. Rinsing the
slides in decreasing concentrations of ethanol was fol-
lowed by antigen unmasking in 10 mM sodium citrate
buffer (pH = 6.0) in a microwave oven at 600 W for 5 min-
utes. After rinsing in distilled H2O, endogenous peroxi-
dase was inhibited by incubation for 10 minutes in 3%
H2O2 in methanol. Slides were then washed with PBS and
incubated with 1% goat serum in PBS for 15 minutes.
Subsequently, slides were incubated with the respective
primary antibodies diluted in antibody diluent (DAKO,
Hamburg, Germany).
After 45–60 minutes of incubation at room temperature,
slides were washed in PBS, incubated with an appropriate
biotinylated secondary antibody (DAKO), washed and
incubated with streptavidin-peroxidase (DAKO). Staining
was visualized by adding 3.3'-diaminobenzidine (DAB;
DAKO) with subsequent counterstaining using haematox-
ylin. Sections were dehydrated in graded ethanol and
embedded in Vitro Clud (Langenbrinck, Germany).
Statistical analysis and clinical correlation
Staining intensities were scored independently by two
observers with experiences in immunohistochemical
investigations. Differences were discussed (no differences
between negative or positive, but some between low and
moderate staining intensity). Scoring grades were 0 (neg-
ative), 1 (low), 2 (moderate) and 3 (high staining inten-
sity). Examples are shown in Figure 1.
Table 1: Site of primary tumors.
Site n = 29 %
Glandula parotidea 4 13.8
Glandula submandibularis 5 17.2
Glandula sublingualis 1 3.5
Minor salivary glands 10 34.5
Nasal cavity and paranasal sinus 9 31.0Page 2 of 8
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Table 2: Used antibodies, source and dilution.
Antibody Clone/species Source Dilution Positive control
p-AKT ab28821 polyclonal rabbit Abcam, Cambridge, UK 1:100 glioblastoma multiforme
TKTL-1 JFC12T10 monoclonal mouse Linaris, Wertheim, Germany 1:200 colorectal adenocarcinoma
M2PK DF4 ScheBo Biotech, Gießen, Germany 1:250 colorectal adenocarcinoma
GLUT-1 polyclonal rabbit DAKO, Hamburg, Germany 1:100 epidermis
Ki67 MIB-1 DAKO, Hamburg, Germany 1:200 tonsil
Examples for immunohistochemical staining results: row 1: p-AKT, row 2: TKTL-1, row 3: M2PK, row 4: GLUT-1; column 1: negativ  (n  negative ca e was found when M2PK was stained), column weak, column 3: moderate, column 4: strongFi ure 1
Examples for immunohistochemical staining results: row 1: p-AKT, row 2: TKTL-1, row 3: M2PK, row 4: 
GLUT-1; column 1: negative (no negative case was found when M2PK was stained), column 2: weak, column 3: 
moderate, column 4: strong.
Diagnostic Pathology 2009, 4:18 http://www.diagnosticpathology.org/content/4/1/18Statistical tests were done using the SPSS software package
(version 14.0.1, Chicago, IL). Charcteristics are presented
at means with their SD values for normally distributed
variables. The significance level was set at α = 5% for all
comparisons. Significances were assessed with log-rank
statistics, Kendall rank correlation, U-Test by Mann and
Whitney, or chi-square test. The cox proportional hazards
model was used for the multivariate analysis.
Ethics
The ethic approval for this study was obtained from Ethic
Committee of the Medical Faculty of University Wuerz-
burg. The study was performed in accordance to the Hel-
sinki declaration.
Results
Patient's median age was 58 years (±15, 32–86 years). 16/
29 (55.2%) of patients were free of relapses after initial
surgery. The remaining patients developed relapses within
2–94 months after initial surgery (median 35 months).
Figure 2 shows the overall relapsing course. If relapsing, 6
patients had more than one relapse (2–4). The site of pri-
mary and risk for relapse did not significantly correlate in
this cohort (P = 0.1). However, 70% (7/10) of tumors
located in the major salivary glands were disease-free after
initial therapy, whereas the majority of relapses arose
from tumors of other sites (76.9%). The tumor stage did
not influence the risk for relapse in this study.
Comparing the staining results of primaries and relapses
of each single patient, no significant differences were
found (P > 0.8, U-Test by Mann and Whitney). Therefore,
in the following the overall staining results are reported.
The proliferation (Ki67) reached from <10% up to 50% in
primaries and relapses. The differences were not signifi-
cant and did not show a trend to higher proliferation in
relapsing cases. Figure 3 shows the results and distribution
of immunohistochemical staining. Significant correla-
tions of different staining results are given in table 3. Inter-
estingly, elder patients showed a significant lower
expression of M2PK (tau = -0.28, P = 0.031, Kendall rank
correlation). For the different sites, tumors of nasal cavity
or paranasal sinuses stained weaker for TKTL-1 than oth-
ers. Staining intensities were distributed equally in all
tumors with 80–100% positive tumor cells. A focal stain-
ing was not observed.
The multivariate analysis for the predictive role of differ-
ent factors regarding the relapse risk is indicated in table
4. Apart from well known parameters (status of complete
surgical resection), expression of p-AKT was significantly
(P = 0.036) associated with a higher relapse risk. Further-
more, lower expression of M2PK was a non-significant (P
= 0.065) predictor for a higher relapse risk.
Relapsing course (overall) with 95% confidence intervalFigure 2











0 1 2 3 4 5 6 7
Relapse free survival n=29
Time [years]Page 4 of 8
(page number not for citation purposes)
Diagnostic Pathology 2009, 4:18 http://www.diagnosticpathology.org/content/4/1/18Discussion
Since Otto Warburg has published his hypothesis of the
importance of glucose metabolism in tumor cells, many
studies have been published regarding this issue. The
influence of PI3K-AKT pathway, glucose transporter
GLUT-1 and M2 pyruvate kinase on glycolysis was dem-
onstrated in several investigations [11,12,15]. In addition,
transketolase-like-1 (TKTL-1) was postulated to play also
an important role in the glucose metabolism of tumors
[17]. To our knowledge, this is the first study which eluci-
dates the role of the markers mentioned above in adenoid
cystic carcinomas (ACC) of head and neck.
All markers were expressed in ACC of our cohort. In all
tumors, 80–100% of tumor cells were positive stained.
Therefore we did not respect the percentage of positive
cells in the analysis. However, in other tumors we found a
more heterogeneous distribution of staining. The cause
could be the more homogeneous tumor differentiaton in
cribriforme ACC compared e.g. with squamous cell carci-
nomas or glioblastomas [7,8].
The expression of p-AKT was found as an independent
parameter for higher relapse risk in ACC, apart from well
documented predictors like incomplete surgical resection,
which we also found correlated significantly with higher
potential for relapsing. Activation and phosphorylation of
the Akt/protein kinase B (AKT) by phosphatidylinositol 3-
kinase (PI3K) often appears in malignant tumors [11,18].
Phosphorylated AKT leads to increasing proliferation,
tumor growth and decreasing apopotosis as well as stim-
ulation of aerobic glycolysis in tumor cells. Elstrom et al.
suggest that the activation of AKT could be responsible for
the metabolic processes during the so-called Warburg
effect [8,11,18]. One possible reason for AKT activation in
ACC was shown by Hu et al., who found an expression of
epiregulin (a member of epidermal growth factor family)
in ACC cell lines with a higher metastatic risk [19].
Results of immunohistochemical staining results in 29 adenoid cystic carcinomasFig re 3
Results of immunohistochemical staining results in 29 adenoid cystic carcinomas. Staining intensity (Score): 0-neg-
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Table 3: Correlation between different staining results (Kendall 
rank correlation).
Stainings tau P
p-Akt TKTL-1 0.3848 0.0034
p-Akt M2PK 0.4015 0.0022
TKTL-1 Glut-1 0.2650 0.044
TKTL-1 M2PK 0.5395 <0.00005Page 5 of 8
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in this study were not significantly associated with higher
relapsing potential, despite the fact that they were found
associated with worse clinical outcome in other malignant
tumors.
TKTL-1 was postulated to be one of three isoforms of the
thiamine-diphosphat dependent enzyme transketolase,
which plays an important role in the pentose phosphate
pathway (PPP) of anaerobic glycolysis [17]. This oxygen-
independent pathway serves as an important source for
the generation of NADPH2 needed in reductive biosynthe-
sis (for example fatty acid synthesis), but more important
is its role in nucleic acid ribose synthesis utilizing glucose
carbons. More than 85% of ribose recovered from tumor
cells is descended from this pathway. Therefore, transke-
tolase upregulation in tumor progression seems very
likely. We could show an expression of TKTL-1 in ACC as
well as in some other malignant tumors [7,8,10]. How-
ever, the expression was not associated with relapse risk or
survival. In other studies, tumors with an aggressive clini-
cal course were investigated (e.g. glioblastomas [8]),
whereas ACC grows comparatively slow. Only few ACC
showd a strong expression of TKTL-1, more often the
expression was only weak. With the background of the
importance of the PPP in nucleic acid ribose synthesis, our
findings fit with the slow growth of ACC. In accordance
with the present results, we have not found a correlation
between TKTL-1 expression and prognosis in tumors of
lower malignancy like astrocytomas <grade IV or granu-
losa cell tumors of ovary [8,9].
The non-predictive value of M2PK and GLUT-1 can be
assumed in the same context. The glycolytic M2 pyruvate
kinase isoenzyme (M2PK) plays a key role by channelling
glucose carbons either into synthetic processes or towards
glycolytic energy production, the former reactions being
catalyzed by the dimeric form of M2PK, the latter by its
tetrameric form. The dimeric form of M2PK is characteris-
tic for tumor cells [12] resulting in an accumulation of gly-
colytic metabolites, which are canalized into synthetic
processes such as amino acid production or nucleic acid
synthesis via the pentosephosphate cycle. Despite non-
significant results, similar to other tumors a lower degree
of M2PK expression tends to be an unfavorable parameter
for prognosis. Interestingly, in our cohort elderly showed
Table 4: Multivariate analysis for relapse risk revealed expression of p-AKT and incomplete resection as prognostic parameters.
beta SD (β) HR 68%-CI von HR P (Chi square)
incomplete resection 12.830 6.505 max 558.725 max 0.049
TKTL-1 1.264 0.909 3.538 1.426 8.781 0.16
p-Akt 4.858 2.394 128.739 11.754 1410.095 0.042
Glut-1 1.100 0.880 3.003 1.245 7.244 0.21
M2PK -5.252 2.818 0.005 0.000 0.088 0.062
incomplete resection 9.811 5.436 18238.626 79.491 max 0.071
TKTL-1 1.255 0.865 3.506 1.476 8.328 0.15
p-Akt 4.188 2.162 65.911 7.588 572.488 0.053
M2PK -4.400 2.508 0.012 0.001 0.151 0.079
incomplete resection 5.962 2.814 388.324 23.289 6474.919 0.034
p-Akt 2.662 1.167 14.331 4.461 46.032 0.023
M2PK -2.092 1.132 0.123 0.040 0.383 0.065
incomplete resection 2.713 1.236 15.080 4.380 51.916 0.028
p-Akt 1.109 0.529 3.032 1.787 5.143 0.036Page 6 of 8
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ated with another relapse risk in this subgroup. The
expression and functionality of glucose transporters
(GLUT) in tumors is probably related to a number of fac-
tors. In this context, the role of oncogenes and tumor
hypoxia has generated a considerable interest [20]. In
squamous cell carcinomas and other malignancies,
hypoxia induces a higher expression of GLUT [21]. The
expression of GLUT-1 was found in several malignant
tumors, but not always in correlation with prognosis
[9,13-15]. In our study, GLUT-1 was expressed in the
majority of ACC, however the expression was mostly
weak. Therefore we assume that hypoxia may play an
minor role in progression of ACC. Further investigations
regarding this point seems necessary (e.g. investigation of
hypoxia inducible factor HIF-1α and correlation with
GLUT and a prospective study of GLUT function in ACC
with 18-FDG-PET).
Due to the missing significance of TKTL-1, M2PK and
GLUT-1, an influence of a glycolytic phenotype is not
proved as parameter of the tumor progression of ACC.
However, further studies with other markers seem neces-
sary. Nevertheless, there was a correlation between expres-
sion of p-AKT and TKTL-1 as well as M2PK, so that the
connection between these parameters reported in the lit-
erature seems once more plausible [8].
Conclusion
Expression of p-AKT is associated with a higher relapse
risk in adenoid cystic carcinomas of salivary glands. In
absence of other predictive parameters apart from tumor
subtype and status of resection, the immunohistochemi-
cal staining could help to assess the individual risk for a
more aggressive course of disease. Moreover, our observa-
tion is in particular important, hence investigations and
clinical trials regarding the therapeutic target of the PI3K-
AKT pathway are ongoing [22,23].
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